Compound C Inhibits Renca Renal Epithelial Carcinoma Growth in Syngeneic Mouse Models by Blocking Cell Cycle...

Area of Science:

• Oncology
• Molecular Biology
• Pharmacology

Background:

• Renal cell carcinoma (RCC) presents significant therapeutic challenges.
• Identifying novel therapeutic agents targeting RCC proliferation and metastasis is crucial.

Purpose of the Study:

• To investigate the molecular mechanisms behind Compound C's (CompC) anti-proliferative effects in renal carcinoma.
• To evaluate CompC's efficacy in inhibiting Renca xenograft growth in vivo.

Main Methods:

• Flow cytometry and Western blot analysis were employed to study Renca cells.
• In vitro assays assessed cell adhesion, migration, and invasion.
• A syngeneic BALB/c mouse model was used to examine Renca xenograft growth.

Main Results:

• CompC reduced platelet-derived growth factor receptor signaling and increased ERK1/2 activation and reactive oxygen species (ROS) production.
• CompC induced G2/M cell cycle arrest by altering Wee1, Cdk1, and histone H3 activity.
• CompC inhibited Renca cell adhesion, migration, invasion, and reduced in vivo tumor growth.

Conclusions:

• CompC-induced G2/M cell cycle arrest, mediated by ROS-dependent ERK1/2 activation and downstream signaling alterations, contributes to reduced cell viability.
• CompC demonstrates therapeutic potential against renal carcinoma by inhibiting cell cycle progression, adhesion, migration, and invasion.